PD1 Blockade and Oncolytic Virus in Relapsed Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2019
Price : $35 *
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Nivolumab (Primary) ; Pelareorep (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 12 Dec 2018 According to an Oncolytics Biotech media release, first patient was treated in this trial.
- 26 Oct 2018 Planned End Date changed from 31 Jul 2025 to 31 Oct 2024.
- 26 Oct 2018 Planned primary completion date changed from 31 Jul 2022 to 31 Oct 2021.